1,54 €
3,82 % gestern
L&S, 2. Mai, 22:55 Uhr
ISIN
US1570851014
Symbol
CERS
Berichte

Cerus Corporation Aktie News

Neutral
Seeking Alpha
41 Minuten alt
Cerus Corporation (NASDAQ:CERS ) Q1 2024 Results Conference Call May 2, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President of Regulatory and Quality Conference Call Participants Emily Chri...
Neutral
Business Wire
etwa 4 Stunden alt
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2024. Recent highlights include: First-quarter 2024 total revenue was comprised of (in thousands, except %): Three Months Ended March 31, Change 2024   2023   $   % Product Revenue $ 38,365 $ 30,974 $ 7,391   24% Government Contract Revenue   5,030   7,502  ...
Neutral
Business Wire
14 Tage alt
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business over...
Neutral
Business Wire
etwa ein Monat alt
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set c...
Neutral
Business Wire
etwa ein Monat alt
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measur...
Neutral
Seeking Alpha
etwa 2 Monate alt
Cerus Corporation (NASDAQ:CERS ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Kevin Green - Vice President Finance and Chief Financial Officer Vivek Jayaraman - Chief Operating Officer Carol Moore - Senior Vice President of Regulatory Affairs and Quality C...
Neutral
Business Wire
etwa 2 Monate alt
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent highlights include: Fourth-quarter 2023 and full-year 2023 total revenue was comprised of (in thousands, except %):   Three Months Ended           Twelve Months Ended           December 31,   Change   December 31,   Change     ...
Neutral
Business Wire
2 Monate alt
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a gener...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen